戻る Agenda
Session 7 - Pediatric Safety
Session Chair(s)
Andrew Mulberg, MD
Senior Vice President
Neurogene, United States
Speaker(s)
FDA's Approach to Assessing Postmarketing Safety Issues in Pediatrics
Ann McMahon, DrMed, MS
FDA, United States
Director of KidNet, Deputy Director of Science, OPT, OC
Long Term Safety Considerations: Why are they so Difficult?
Robert L Davis, MD, MPH
University of Tennessee Health Sciences Center , United States
Governor's Chair and Director, Center for Biomedical Informatics
Risky Business: When Children are First-in-Line for Experimental Treatments
Robert "Skip" Nelson, MD, PHD
Johnson & Johnson, United States
Executive Director, Pediatric Drug Development (CHILD)